IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease

Circ J. 2010 May;74(5):983-9. doi: 10.1253/circj.cj-09-0801. Epub 2010 Mar 26.

Abstract

Background: The literature regarding interleukin (IL)-10 polymorphisms and coronary artery lesions (CALs) in Kawasaki disease (KD) is limited. We investigated whether 3 IL-10 genetic polymorphisms (-1082 A/G, -819 T/C, and -592 A/C) are associated with development of CALs in KD.

Methods and results: The genotyping of IL-10 polymorphisms was conducted for 279 KD children (172 without and 107 with CALs in acute stage). Thirty-three patients had CALs in chronic stage and 74 only with transient CALs. The homozygous variant genotype CC of IL-10-819 and IL-10-592 was associated with 80% (P=0.006) and 79% (P=0.008) reduction in risk of CALs in acute stage, respectively. The C allele of IL-10-819 and IL-10-592 was associated with 34% (P=0.034) and 33% (P=0.044) reduction in risk of CALs in acute stage, respectively. Compared with ATA haplotype (adjusted odds ratio (AOR) 0.63, P=0.029) or non-ACC haplotype (AOR 0.64, P=0.033), ACC haplotype was associated with a significantly reduced risk for CALs in acute stage, but not for CALs in chronic stage. Compared with non-ATA haplotype (AOR 1.53, P=0.034), ATA haplotype was associated with a significantly increased risk of CALs, except for CALs in the chronic stage.

Conclusions: The effects of IL-10 gene polymorphism on CALs in acute KD are important. The persistence of CALs in chronic stage depends much more on other factors such as the times of intravenous immunoglobulin treatment.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Alleles*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Coronary Disease / drug therapy
  • Coronary Disease / genetics*
  • Coronary Disease / pathology
  • Coronary Vessels / pathology
  • Female
  • Haplotypes
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunologic Factors / administration & dosage
  • Infant
  • Interleukin-10 / genetics*
  • Male
  • Mucocutaneous Lymph Node Syndrome / drug therapy
  • Mucocutaneous Lymph Node Syndrome / genetics*
  • Mucocutaneous Lymph Node Syndrome / pathology
  • Polymorphism, Genetic*
  • Retrospective Studies
  • Risk Factors

Substances

  • IL10 protein, human
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Interleukin-10